E
2.32
0.52 (28.61%)
AIStockmoo 评分
| 价值 35% | 0.0 |
| AI Insight 参考 | NA |
| 相对估值 参考 | NA |
| 财务健康 参考 | 0.0 |
| 时机 35% | 1.2 |
| AI Technical 参考 | NA |
| 技术振荡指标 参考 | 2.0 |
| 技术平均移动指标 参考 | 0.0 |
| 聪明钱 30% | 0.0 |
| 分析师共识 参考 | 0.0 |
| 内部交易活动 参考 | NA |
| 新闻情绪 参考 | NA |
| 市场环境 | ×0.79 |
| 宏观环境 参考 | -3.3 |
| 行业对比大市 (6个月) | -23.0% |
| 支柱一致性 | ×1.00 |
| 不计入评分 | |
| 价格波动 参考 | -0.1 |
| 最终评分 | 0.33 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | enGene Therapeutics Inc. | 混合的 | 看涨 |
相关股票
| 股票 | 市值 | DY | P/E（TTM） | P/B |
|---|---|---|---|---|
| ENGN | - | - | - | 0.530 |
| TRML | 1 B | - | - | 4.76 |
| IOVA | - | - | - | 4.60 |
| DBVT | - | - | - | 4.87 |
| JANX | - | - | - | 0.810 |
| CRNX | - | - | - | 7.56 |
|
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 13.63% |
| 机构持股比例 | 77.57% |
该时间范围内无数据。
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 11 Nov 2026 | Yahoo Finance |
enGene Appoints Key Executives in Anticipation of Upcoming Regulatory and Commercial Milestones
BOSTON & MONTREAL, November 11, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN) ("enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced the appointments of Erik T. Goluboff, MD, MBA as Chief Medical Officer and Jason Duncan as Chief Legal and Administrative… |
| 11 Nov 2026 | Yahoo Finance |
enGene to Initiate a BLA Submission for Detalimogene by Year End and Reports New Data from LEGEND Trial Pivotal Cohort 1 in BCG-Unresponsive NMIBC
BOSTON & MONTREAL, November 11, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced updated results from the pivotal Cohort 1 of its ongoing, Phase 2 LEGEND trial of detalimogene voraplasmid (also known as… |
| 06 Nov 2026 | Yahoo Finance |
enGene to Participate in Upcoming Investor Conferences
BOSTON & MONTREAL, November 06, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company today announced that management will participate in the following investor conferences:… |
| 16 Oct 2026 | Yahoo Finance |
enGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update Path
enGene (NASDAQ:ENGN) used a company webinar to outline preclinical findings for its investigational non-viral gene therapy, detalimogene voraplasmid, used with a polidocanol surfactant bladder rinse, while community urologists discussed the treatment burden facing patients with high-risk non-muscle… |
| 13 Oct 2026 | Yahoo Finance |
enGene to Host KOL Webinar on October 15, 2026
BOSTON & MONTREAL, October 13, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced that it will host a webinar on Thursday, October 15, 2026 at 10:00 AM ET that will provide greater detail on the… |
| 08 Sep 2026 | Yahoo Finance |
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
BOSTON & MONTREAL, September 08, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the third quarter ended July 31, 2026, and provided clinical and corporate updates. |
| 13 Aug 2026 | Yahoo Finance |
enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market
enGene (NASDAQ:ENGN) outlined its view of the high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer, or NMIBC, market, citing market research that it believes supports a larger addressable patient population and greater use of treatment sequencing before radical cystecto… |
投资组合